Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Transparency and Access for Healthcare Consumers

Transparency in healthcare is vital to help avoid or reduce the varying disparities that exist and continue to burden the overall medical field in this country. Technology in healthcare is growing and has mitigated some of these disparities, even helping close some of the gaps that have been magnified. But there is still more progress…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Transparency in healthcare is vital to help avoid or reduce the varying disparities that exist and continue to burden the overall medical field in this country. Technology in healthcare is growing and has mitigated some of these disparities, even helping close some of the gaps that have been magnified. But there is still more progress to be made and seen as access remains a top concern.

What kinds of technological advances can help improve healthcare access?

Discussing this subject on the newest episode of Highway to Health, host David Kemp interviewed Paul Ketchel, CEO and Co-Founder of MDSave, a platform that helps healthcare consumers compare and weigh medical costs and prices. The two talked about the state of healthcare today, what areas need improvement, and how his company offers resolutions to some of the issues facing the healthcare industry.

Kemp and Ketchel further explored the topic and talked about …

  1. Ketchel’s background and building a healthcare platform
  2. Ways in which technology is a problem solver
  3. Why and where healthcare technology falls behind in creating access

Ketchel detailed how innovative ideas drive change and how it’s benefitted his own, and naturally his company.

“For me innovation is, you know, using the newest technological advances and tools to solve what has traditionally been very large, difficult problems, or problems we haven’t been able to solve in the past. And fortunately, for companies like mine and maybe unfortunately for the rest of the world, healthcare is full of those problems, and I always tell folks I feel like one thing that’s been disappointing from the view of an innovator is that we’ve not really applied that technology to a lot of areas in healthcare yet,” he said.

He continued, “Things are getting better and we’re trying, but you know I think it’s safe to say we’re probably 20 solid years behind other sectors,” said Ketchel.

Paul Ketchel is the CEO and Co-Founder of MDSave, Inc., which he helped found in 2012. Before co-founding the company, he was the COO of Diagnostix Network Alliance, LLC for two years and had other roles in government relations and business development. Ketchel is an alumnus of University of Tennessee-Knoxville where here he received a degree in political science.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512